AR036659A1 - Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos - Google Patents
Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentosInfo
- Publication number
- AR036659A1 AR036659A1 ARP020103689A ARP020103689A AR036659A1 AR 036659 A1 AR036659 A1 AR 036659A1 AR P020103689 A ARP020103689 A AR P020103689A AR P020103689 A ARP020103689 A AR P020103689A AR 036659 A1 AR036659 A1 AR 036659A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkenyl
- alkyl
- alkynyl
- phenyl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200101466 | 2001-10-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR036659A1 true AR036659A1 (es) | 2004-09-22 |
Family
ID=8160750
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020103689A AR036659A1 (es) | 2001-10-04 | 2002-09-30 | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos |
ARP080101915A AR066460A2 (es) | 2001-10-04 | 2008-05-06 | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080101915A AR066460A2 (es) | 2001-10-04 | 2008-05-06 | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos |
Country Status (39)
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
GB0305575D0 (en) * | 2003-03-11 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
UA81472C2 (en) * | 2003-04-04 | 2008-01-10 | Lundbeck & Co As H | 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors |
PT1626720E (pt) * | 2003-04-04 | 2008-11-10 | Lundbeck & Co As H | Derivados de 4-(2-fenilsulfanil-fenil)-piperidina como inibidores da recaptação da serotonina |
KR20050119682A (ko) * | 2003-04-04 | 2005-12-21 | 하. 룬트벡 아크티에 셀스카브 | 세로토닌 재흡수 억제제로서 4-(2-페닐옥시페닐)-피페리딘또는 -1,2,3,6-테트라히드로피리딘 유도체 |
UA81300C2 (en) * | 2003-04-04 | 2007-12-25 | Lundbeck & Co As H | Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture |
ATE392896T1 (de) * | 2003-04-04 | 2008-05-15 | Lundbeck & Co As H | 4-(2-phenyloxyphenyl)-piperidin- oder -1,2,3,6- tetrahydropyridin-derivate als serotonin- wiederaufnahme-hemmer |
PL1701940T3 (pl) | 2003-12-23 | 2008-11-28 | H Lundbeck As | Pochodne 2-(1H-indolilosulfanylo)benzyloaminy jako SSRI |
AR052308A1 (es) | 2004-07-16 | 2007-03-14 | Lundbeck & Co As H | Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto |
US7923444B2 (en) | 2005-02-10 | 2011-04-12 | Neurosearch A/S | Alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
AR054393A1 (es) * | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos. |
US7629473B2 (en) | 2005-06-17 | 2009-12-08 | H. Lundbeck A/S | 2-(1H-indolylsulfanyl)-aryl amine derivatives |
AR054394A1 (es) * | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de 2- (1h-indolilsulfanil)-aril amina |
JP2007106746A (ja) * | 2005-09-13 | 2007-04-26 | Tosoh Corp | 新規アリールホモピペラジン類、またはその塩と製造方法 |
AU2007260356B2 (en) * | 2006-06-16 | 2013-01-24 | H. Lundbeck A/S | Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
MY150698A (en) * | 2006-06-16 | 2014-02-28 | Lundbeck & Co As H | Crystalline forms of 4- [2- (-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
JP7179035B2 (ja) * | 2006-06-16 | 2022-11-28 | ハー・ルンドベック・アクチエゼルスカベット | 認識機能障害(cognitive impairment)を治療するための、組み合わされたセロトニン再取り込み、5-HT3および5-HT1A活性を有する化合物としての1-[2-(2,4-ジメチルフェニルスルファニル)-フェニル]ピペラジン |
CN101472891B (zh) * | 2006-06-16 | 2013-08-21 | H.隆德贝克有限公司 | 有神经病痛治疗用血清素和去甲肾上腺素再摄取综合抑制作用的4-[2-(4-甲基苯硫基)苯基]哌啶的结晶形式 |
CN102614179B (zh) | 2006-06-16 | 2015-11-25 | H.隆德贝克有限公司 | 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5-ht3和5-ht1a活性的化合物的1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪 |
TW200848411A (en) * | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
TWI432194B (zh) | 2007-03-20 | 2014-04-01 | Lundbeck & Co As H | 4-〔2-(4-甲基苯硫基)苯基〕哌啶之新穎治療用途 |
TWI405588B (zh) * | 2007-03-20 | 2013-08-21 | Lundbeck & Co As H | 4-〔2-(4-甲苯基硫基)-苯基〕哌啶之鹽類的液體調配物 |
JP5764327B2 (ja) * | 2007-06-15 | 2015-08-19 | ハー・ルンドベック・アクチエゼルスカベット | 過敏性腸症候群(ibs)を処置するための4−[2−(4−メチルフェニルスルファニル)フェニル]ピペリジン |
AU2014200364B2 (en) * | 2007-11-13 | 2015-09-17 | H. Lundbeck A/S | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity |
TW200932233A (en) † | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
TW200938194A (en) * | 2007-12-14 | 2009-09-16 | Lundbeck & Co As H | Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter |
TW200932225A (en) * | 2007-12-14 | 2009-08-01 | Lundbeck & Co As H | 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine |
WO2009081259A1 (en) * | 2007-12-21 | 2009-07-02 | Pfizer Inc. | Phenoxy-pyridyl derivatives |
UA98698C2 (en) * | 2008-03-03 | 2012-06-11 | Х. Луннбек А/С | Phenylsulfanylphenyl-piperidines and process for the preparation thereof |
PT2358674E (pt) | 2008-11-14 | 2013-03-05 | Theravance Inc | Processo de preparação de compostos de 4-[2-(2-fluorofenoximetil)fenil]piperidina |
TW201033181A (en) | 2009-02-17 | 2010-09-16 | Lundbeck & Co As H | Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
JP5722879B2 (ja) * | 2009-04-24 | 2015-05-27 | ハー・ルンドベック・アクチエゼルスカベット | 1−[2−(2,4−ジメチルフェニルスルファニル)フェニル]ピペラジンの塩の液体製剤 |
SI2470166T1 (sl) | 2009-08-24 | 2014-03-31 | H.Lundbeck A/S | Novi sestavki 1-(2-(2,4-dimetil-fenislulfanil)-fenil)piperazina |
CA2779108C (en) * | 2009-10-30 | 2018-01-02 | Janssen Pharmaceutica Nv | 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators |
WO2011085291A1 (en) * | 2010-01-11 | 2011-07-14 | Theravance, Inc. | 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors |
EP2550252B1 (en) * | 2010-03-22 | 2015-05-06 | Theravance Biopharma R&D IP, LLC | 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds |
KR101820181B1 (ko) * | 2010-04-30 | 2018-02-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 장용성 정제 |
KR20130060220A (ko) * | 2010-04-30 | 2013-06-07 | 다케다 야쿠힌 고교 가부시키가이샤 | 장용성 정제 |
EP2407467A1 (de) | 2010-07-14 | 2012-01-18 | Sandoz Ag | Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure |
TW201212918A (en) * | 2010-08-23 | 2012-04-01 | Lundbeck & Co As H | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine |
LT2720989T (lt) | 2011-06-20 | 2016-11-25 | H. Lundbeck A/S | Deuterinti 1-piperazin-3-fenilindanai, skirti šizofrenijos gydymui |
JP6285865B2 (ja) | 2011-11-14 | 2018-02-28 | アルファシグマ ソシエタ ペル アチオニ | うつ病を有する対象のための処置レジメンを選択するためのアッセイ及び方法 |
LT2800746T (lt) | 2012-01-03 | 2019-06-10 | H. Lundbeck A/S | 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazino gavimo būdas |
WO2014044721A1 (en) | 2012-09-19 | 2014-03-27 | Sandoz Ag | Novel crystalline form of vortioxetine hydrobromide |
ES2663680T3 (es) | 2012-12-13 | 2018-04-16 | H. Lundbeck A/S | Composiciones que comprenden vortioxetina y donepezilo |
RU2652265C2 (ru) * | 2013-02-22 | 2018-04-27 | Х. Лундбекк А/С | Способ получения вортиоксетина |
CN105283442B (zh) * | 2013-04-04 | 2018-04-13 | 斯洛文尼亚莱柯制药股份有限公司 | 用于合成1‑(2‑((2,4‑二甲基苯基)硫代)苯基)哌嗪的方法 |
CN104109135B (zh) * | 2013-04-22 | 2018-10-26 | 江苏豪森药业集团有限公司 | 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法 |
IN2013MU03121A (US06650917-20031118-M00005.png) | 2013-09-30 | 2015-07-17 | Cadila Healthcare Ltd | |
EP2878596A1 (en) * | 2013-11-29 | 2015-06-03 | LEK Pharmaceuticals d.d. | Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates |
CN104710345B (zh) * | 2013-12-17 | 2017-09-05 | 江苏恩华药业股份有限公司 | 用于制备4‑(2‑(4‑甲基苯基硫基))苯基哌啶的化合物、其制备方法及应用 |
KR20160093025A (ko) | 2013-12-20 | 2016-08-05 | 하. 룬트벡 아크티에 셀스카브 | 멜랑코리성 특색을 갖는 우울 장애의 치료를 위한 카파-활성을 갖는 오피오이드 수용체 길항제 및 보티옥세틴의 용도 |
EP2894154A1 (en) | 2014-01-14 | 2015-07-15 | LEK Pharmaceuticals d.d. | Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates |
CN103788019B (zh) * | 2014-01-22 | 2015-10-07 | 苏州明锐医药科技有限公司 | 沃替西汀的制备方法 |
EA029060B1 (ru) | 2014-01-31 | 2018-02-28 | Эгиш Дьёдьсердьяр Зрт. | Способ получения солей вортиоксетина |
EP2930171A1 (en) | 2014-04-07 | 2015-10-14 | LEK Pharmaceuticals d.d. | Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate |
CN104059030B (zh) * | 2014-05-30 | 2016-05-04 | 镇江圣安医药有限公司 | [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途 |
FR3023320B1 (fr) * | 2014-07-03 | 2017-03-10 | Ifp Energies Now | Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial |
CZ2014471A3 (cs) | 2014-07-08 | 2016-01-20 | Zentiva, K.S. | Způsob přípravy vortioxetinu |
US9687484B2 (en) | 2014-07-18 | 2017-06-27 | Dipharma Francis S.R.L. | Crystalline forms of an antidepressant compound |
CN104146953A (zh) * | 2014-07-24 | 2014-11-19 | 李雪梅 | 一种氢溴酸沃替西汀注射液 |
CN104292183B (zh) * | 2014-09-29 | 2016-01-06 | 杨献美 | 一种抗抑郁药物沃替西汀的制备方法 |
WO2016079751A2 (en) | 2014-11-17 | 2016-05-26 | Megafine Pharma (P) Ltd. | A process for preparation of vortioxetine and polymorphs thereof |
EP3023417B1 (en) | 2014-11-21 | 2017-06-28 | Dipharma Francis S.r.l. | Process for the preparation of an antidepressant and the intermediates thereof |
CN104447622B (zh) * | 2014-11-28 | 2017-01-04 | 郑州大明药物科技有限公司 | 氢溴酸沃替西汀β晶型的制备方法 |
CN104586756A (zh) * | 2015-01-05 | 2015-05-06 | 万特制药(海南)有限公司 | 一种含沃替西汀的口服溶液及其制备方法 |
CZ201531A3 (cs) | 2015-01-21 | 2016-08-03 | Zentiva, K.S. | Polymerem stabilizované amorfní formy vortioxetinu |
CN104610195B (zh) * | 2015-01-30 | 2017-06-27 | 上虞京新药业有限公司 | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 |
WO2016125190A2 (en) | 2015-02-04 | 2016-08-11 | Mylan Laboratories Limited | Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof |
WO2016125191A2 (en) | 2015-02-04 | 2016-08-11 | Mylan Laboratories Limited | Processes for the preparation of vortioxetine hydrobromide |
EP3262031A1 (en) | 2015-02-25 | 2018-01-03 | Lupin Limited | Process for the preparation of vortioxetine |
WO2016151328A1 (en) | 2015-03-26 | 2016-09-29 | Cipla Limited | Method for making serotonin reuptake inhibitors |
CN104829557B (zh) * | 2015-04-23 | 2017-06-27 | 山东百诺医药股份有限公司 | 一种新化合物1‑[2‑(2,4‑二甲基苯基硫基)苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用 |
JO3456B1 (ar) | 2015-05-13 | 2020-07-05 | H Lundbeck As | فيروتيوكسيتين بيروجلوتامات |
JP7000321B2 (ja) | 2015-07-17 | 2022-02-10 | アンスティテュ・パストゥール | 衛星細胞の自己再生および/または分化の促進剤としての使用のための5-ヒドロキシトリプタミン1b受容体刺激剤 |
EP3337789A1 (en) * | 2015-08-19 | 2018-06-27 | Amneal Pharmaceuticals Company GmbH | Process for preparation of vortioxetine hydrobromide |
WO2017063771A1 (en) * | 2015-10-14 | 2017-04-20 | Institut Pasteur | 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction |
CN105348204B (zh) * | 2015-11-18 | 2018-09-14 | 乳源瑶族自治县大众药品贸易有限公司 | 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途 |
CN105461635B (zh) * | 2015-11-18 | 2018-06-08 | 乳源瑶族自治县大众药品贸易有限公司 | 苯基哌嗪衍生物及其使用方法和用途 |
US11013830B2 (en) * | 2015-11-20 | 2021-05-25 | Institut Pasteur | 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential |
WO2017162536A1 (en) | 2016-03-21 | 2017-09-28 | H. Lundbeck A/S | Vortioxetine prodrugs |
CN109310691A (zh) | 2016-07-01 | 2019-02-05 | H.隆德贝克有限公司 | 用于快速开始抗抑郁作用的给药方案 |
KR20190038840A (ko) * | 2016-07-15 | 2019-04-09 | 앵스띠뛰 파스퇴르 | 피부 및/또는 모발 복구를 위한 5-하이드록시트립타민 1b 수용체-자극제 |
CN109890799A (zh) * | 2016-07-22 | 2019-06-14 | 江苏恩华络康药物研发有限公司 | 沃替西汀类似物及其用途和制备 |
US20190224192A1 (en) | 2016-08-29 | 2019-07-25 | Cipla Limited | Stable Pharmaceutical Composition of Vortioxetine Hydrobromide |
CN106349132B (zh) * | 2016-08-30 | 2018-02-02 | 重庆植恩药业有限公司 | 沃替西汀中间体杂质及其制备方法和用途 |
US10519121B2 (en) | 2016-12-30 | 2019-12-31 | Apicore Us Llc | Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts |
CN108409728B (zh) * | 2017-02-09 | 2020-11-24 | 广东东阳光药业有限公司 | 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途 |
CN108409729B (zh) * | 2017-02-09 | 2020-11-24 | 广东东阳光药业有限公司 | 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途 |
US10428033B2 (en) | 2017-02-15 | 2019-10-01 | Piramal Enterprises Limited | Process for the preparation of vortioxetine and salts thereof |
WO2018150344A1 (en) | 2017-02-17 | 2018-08-23 | Unichem Laboratories Ltd | Bioequivalent pharmaceutical composition of vortioxetine hydrobromide |
WO2018154451A1 (en) * | 2017-02-23 | 2018-08-30 | Unichem Laboratories Ltd | An improved process for preparation and purification of vortioxetine hydrobromide |
HRP20220108T1 (hr) | 2017-04-25 | 2022-04-15 | H. Lundbeck A/S | Postupak za proizvodnju vortioksetina hbr alfa-oblika |
EP3412661A1 (en) | 2017-06-08 | 2018-12-12 | Enantia, S.L. | Cocrystals of vortioxetine hydrobromide and resorcinol |
KR102026337B1 (ko) | 2017-07-07 | 2019-09-27 | 영진약품 주식회사 | 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법 |
CN107915685A (zh) * | 2017-12-11 | 2018-04-17 | 重庆植恩药业有限公司 | 一种氢溴酸沃替西汀中间体的制备方法 |
CN108017595A (zh) * | 2017-12-20 | 2018-05-11 | 安徽源久源科技有限公司 | 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法 |
US11198671B2 (en) | 2018-06-20 | 2021-12-14 | Vio Ag Pharmaceuticals S.A. | One-pot organo-pseudocatalytic C—H activation approach for the preparation of vortioxetine and vortioxetine intermediate |
CN108863986B (zh) * | 2018-08-06 | 2020-01-21 | 广东东阳光药业有限公司 | 二氟甲基取代的苯基哌嗪衍生物及其用途 |
CN108727393B (zh) * | 2018-08-06 | 2019-10-29 | 广东东阳光药业有限公司 | 苯基二氮杂双环衍生物及其用途 |
AU2021246973A1 (en) | 2020-04-03 | 2022-11-03 | H. Lundbeck A/S | 1-(2-(2,4-dimethylphenylsulfanyl)-phenyl)piperazine for prevention or treatment of emotional blunting |
GB2622880A (en) | 2022-09-30 | 2024-04-03 | Alkaloid Ad Skopje | Palatable orodispersible formulation of vortioxetine |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS151753B1 (US06650917-20031118-M00005.png) | 1971-04-13 | 1973-11-19 | ||
CS151755B1 (US06650917-20031118-M00005.png) | 1971-04-13 | 1973-11-19 | ||
CS151751B1 (US06650917-20031118-M00005.png) | 1971-04-13 | 1973-11-19 | ||
CS151752B1 (US06650917-20031118-M00005.png) | 1971-04-13 | 1973-11-19 | ||
YU163075A (en) * | 1975-07-21 | 1982-05-31 | Science Union & Cie | Process for preparing new phenoxy derivatives |
US4241071A (en) | 1977-01-27 | 1980-12-23 | American Hoechst Corporation | Antidepressant (α-phenyl-2-tolyl)azacycloalkanes |
US4198417A (en) | 1979-01-10 | 1980-04-15 | American Hoechst Corporation | Phenoxyphenylpiperidines |
US4198419A (en) | 1979-01-10 | 1980-04-15 | American Hoechst Corporation | Phenylthiophenylpiperidines |
ES2004809A6 (es) | 1987-07-29 | 1989-02-01 | Ferrer Int | Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas |
GB9126311D0 (en) | 1991-12-11 | 1992-02-12 | Wellcome Found | Substituted diphenylsulfides |
CA2185984C (en) * | 1995-01-23 | 2007-12-04 | Hirokazu Annoura | Medicament for the alleviation or treatment of symptom derived from ischemic disease and compound useful therefor |
CZ293595A3 (cs) | 1995-11-09 | 1999-12-15 | Farmak A. S. | Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích |
FR2757160B1 (fr) * | 1996-12-13 | 1999-03-12 | Sanofi Sa | 1-phenylalkyl-1,2,3,6-tetrahydropyridines |
US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
ES2241169T3 (es) * | 1997-10-31 | 2005-10-16 | Daiichi Suntory Pharma Co., Ltd. | Derivados de arilpiperidinopropanol y arilpiperazinopropanol y productos farmaceuticos que los contienen. |
CN1351588A (zh) | 1999-04-02 | 2002-05-29 | 伊科斯公司 | 白细胞功能相关抗原与细胞间粘着分子结合的抑制剂及其用途 |
BR0012984A (pt) | 1999-08-04 | 2002-07-16 | Millennium Pharm Inc | Método para tratar um estado associado com o mc4-r em um mamìfero, composto de ligação ao mc4-r, e, composição farmacêutica |
CA2384599A1 (en) * | 1999-09-14 | 2001-03-22 | Pharmacopeia, Inc. | Article comprising a multi-channel dispensing head |
JP2003519227A (ja) * | 1999-12-30 | 2003-06-17 | ハー・ルンドベック・アクチエゼルスカベット | 置換されたベンゼン誘導体の製造方法 |
HUP0203722A3 (en) * | 1999-12-30 | 2005-03-29 | Lundbeck & Co As H | Substituted phenyl-piperazine derivatives, pharmaceutical compositions containing them and their use |
US6813639B2 (en) | 2000-01-26 | 2004-11-02 | Viaclix, Inc. | Method for establishing channel-based internet access network |
DE10033548C2 (de) | 2000-07-11 | 2002-05-16 | Wolfgang Papenbrock | Verfahren zur Vorschau von Internetseiten |
ES2247298T3 (es) * | 2001-01-23 | 2006-03-01 | Eli Lilly And Company | Derivados de piperazina y piperidina como agonistas del receptor de melanocortina. |
WO2002062766A2 (en) | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
AU2002351734A1 (en) * | 2001-12-20 | 2003-07-09 | H. Lundbeck A/S | Aryloxyphenlyl and arylsulfanylphenyl derivatives |
AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
PT1626720E (pt) * | 2003-04-04 | 2008-11-10 | Lundbeck & Co As H | Derivados de 4-(2-fenilsulfanil-fenil)-piperidina como inibidores da recaptação da serotonina |
WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
CN102614179B (zh) * | 2006-06-16 | 2015-11-25 | H.隆德贝克有限公司 | 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5-ht3和5-ht1a活性的化合物的1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪 |
-
2002
- 2002-02-10 UA UA2004032271A patent/UA81749C2/uk unknown
- 2002-09-30 AR ARP020103689A patent/AR036659A1/es active IP Right Grant
- 2002-10-02 BR BR122012023120A patent/BR122012023120B8/pt active IP Right Grant
- 2002-10-02 KR KR1020047004897A patent/KR100770194B1/ko active Protection Beyond IP Right Term
- 2002-10-02 HU HU0402313A patent/HU228956B1/hu active Protection Beyond IP Right Term
- 2002-10-02 EP EP06016609A patent/EP1749818B1/en not_active Expired - Lifetime
- 2002-10-02 KR KR1020077022025A patent/KR100842702B1/ko active IP Right Grant
- 2002-10-02 ES ES02800051T patent/ES2298425T7/es active Active
- 2002-10-02 RS RS20120158A patent/RS52865B/en unknown
- 2002-10-02 EP EP02800051.1A patent/EP1436271B3/en not_active Expired - Lifetime
- 2002-10-02 BR BRPI0212733A patent/BRPI0212733B8/pt active IP Right Grant
- 2002-10-02 JP JP2003532482A patent/JP3896116B2/ja not_active Expired - Lifetime
- 2002-10-02 HU HU1300028A patent/HU230189B1/hu unknown
- 2002-10-02 BR BR122012009534D patent/BR122012009534C8/pt not_active IP Right Cessation
- 2002-10-02 DE DE60233608T patent/DE60233608D1/de not_active Expired - Lifetime
- 2002-10-02 US US10/488,280 patent/US7144884B2/en active Active
- 2002-10-02 DK DK06016609T patent/DK1749818T3/da active
- 2002-10-02 EA EA200601269A patent/EA011096B1/ru not_active IP Right Cessation
- 2002-10-02 ME MEP-2008-65A patent/ME00039B/me unknown
- 2002-10-02 PT PT06016609T patent/PT1749818E/pt unknown
- 2002-10-02 EG EG2002101084A patent/EG25095A/xx active
- 2002-10-02 WO PCT/DK2002/000659 patent/WO2003029232A1/en active IP Right Grant
- 2002-10-02 IL IL16065502A patent/IL160655A0/xx active Protection Beyond IP Right Term
- 2002-10-02 UA UAA200612495A patent/UA93857C2/uk unknown
- 2002-10-02 PL PL368442A patent/PL209253B1/pl unknown
- 2002-10-02 DK DK02800051.1T patent/DK1436271T6/da active
- 2002-10-02 PT PT02800051T patent/PT1436271E/pt unknown
- 2002-10-02 PL PL392184A patent/PL210551B1/pl unknown
- 2002-10-02 EA EA200400498A patent/EA007537B3/ru active Protection Beyond IP Right Term
- 2002-10-02 NZ NZ531556A patent/NZ531556A/en not_active IP Right Cessation
- 2002-10-02 AT AT02800051T patent/ATE386730T1/de active
- 2002-10-02 AU AU2002333220A patent/AU2002333220C1/en active Active
- 2002-10-02 CA CA2462110A patent/CA2462110C/en not_active Expired - Lifetime
- 2002-10-02 MX MXPA04002959A patent/MXPA04002959A/es active IP Right Grant
- 2002-10-02 KR KR1020067022562A patent/KR100783346B1/ko active IP Right Grant
- 2002-10-02 AT AT06016609T patent/ATE441631T1/de active
- 2002-10-02 SI SI200230678T patent/SI1436271T1/sl unknown
- 2002-10-02 CN CNB028190254A patent/CN1319958C/zh not_active Expired - Lifetime
- 2002-10-02 ES ES06016609T patent/ES2328725T3/es not_active Expired - Lifetime
- 2002-10-02 DE DE60225162.1T patent/DE60225162T3/de not_active Expired - Lifetime
- 2002-10-02 RS YU27704A patent/RS52326B/en unknown
- 2002-10-03 MY MYPI20023705A patent/MY140950A/en unknown
-
2004
- 2004-02-26 ZA ZA2004/01583A patent/ZA200401583B/en unknown
- 2004-02-26 IS IS7164A patent/IS2578B/is unknown
- 2004-03-05 HR HR20040220A patent/HRP20040220A2/hr not_active Application Discontinuation
- 2004-04-21 NO NO20041628A patent/NO326443B1/no not_active IP Right Cessation
- 2004-04-30 CO CO04039958A patent/CO5580746A2/es not_active Application Discontinuation
-
2005
- 2005-06-23 HK HK05105260A patent/HK1072600A1/xx not_active IP Right Cessation
- 2005-12-06 US US11/296,835 patent/US7138407B2/en not_active Expired - Lifetime
- 2005-12-06 US US11/296,836 patent/US7148238B2/en not_active Expired - Lifetime
-
2006
- 2006-09-14 AU AU2006215994A patent/AU2006215994B2/en not_active Ceased
- 2006-10-03 JP JP2006271762A patent/JP3955614B2/ja not_active Expired - Lifetime
- 2006-10-03 JP JP2006271758A patent/JP3955613B2/ja not_active Expired - Lifetime
- 2006-10-19 US US11/551,188 patent/US7683053B2/en not_active Expired - Fee Related
-
2008
- 2008-04-18 CY CY20081100436T patent/CY1107924T1/el unknown
- 2008-05-06 AR ARP080101915A patent/AR066460A2/es active IP Right Grant
- 2008-08-06 NO NO20083446A patent/NO332355B1/no not_active IP Right Cessation
-
2009
- 2009-03-10 IS IS8806A patent/IS2732B/is unknown
- 2009-10-14 CY CY20091101068T patent/CY1110064T1/el unknown
-
2010
- 2010-02-04 US US12/700,521 patent/US8110567B2/en not_active Expired - Fee Related
-
2012
- 2012-02-06 US US13/367,065 patent/US8476279B2/en not_active Expired - Lifetime
-
2013
- 2013-06-26 US US13/927,678 patent/US9090575B2/en not_active Expired - Fee Related
-
2014
- 2014-03-07 NL NL300652C patent/NL300652I2/nl unknown
- 2014-03-12 LU LU92397C patent/LU92397I2/fr unknown
- 2014-03-12 HU HUS1400012C patent/HUS1400012I1/hu unknown
- 2014-03-13 LT LTPA2014013C patent/LTC1436271I2/lt unknown
- 2014-04-16 FR FR14C0033C patent/FR14C0033I2/fr active Active
- 2014-05-13 NO NO2014011C patent/NO2014011I2/no not_active IP Right Cessation
- 2014-06-03 BE BE2014C036C patent/BE2014C036I2/nl unknown
- 2014-06-11 CY CY2014022C patent/CY2014022I1/el unknown
-
2015
- 2015-06-19 US US14/744,197 patent/US9708280B2/en not_active Expired - Lifetime
-
2017
- 2017-06-15 US US15/624,417 patent/US10844029B2/en not_active Expired - Lifetime
-
2020
- 2020-10-22 US US17/078,055 patent/US20210276966A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR036659A1 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
EA200301306A1 (ru) | Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение | |
SE0201635D0 (sv) | Novel compounds | |
AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
AR032679A1 (es) | Derivados del acido isoftalico como inhibidores de metaloproteinasas de la matriz | |
AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
AR038881A1 (es) | Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos | |
ECSP056016A (es) | Nuevos derivados de 2-piridinacarboxamida | |
AR039566A1 (es) | Inhibidores de la histona deacetilasa, composicion farmaceutica que los contiene y sus procesos de preparacion | |
EA200300718A1 (ru) | Производные 3-индолина, которые могут применяться при лечении психиатрических и неврологических расстройств | |
NO20080391L (no) | Pyrazolbaserte LXR modulatorer | |
AR036598A1 (es) | Derivados de 4,5-dihidro-1h-pirazol que tienen potente actividad antagonista de cb1 | |
SE0303180D0 (sv) | Novel compounds | |
AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
AR039567A1 (es) | Derivados de sulfonilamino como nuevos inhibidores de histona deacetilasa, composicion farmaceutica y procedimiento de preparacion del compuesto | |
SE0302232D0 (sv) | Novel Compounds | |
AR029301A1 (es) | Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos | |
CL2008002654A1 (es) | Compuestos derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, bloqueadores de los canales hcn; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cardiopatias isquemicas, insuficiencias cardiacas tanto sistolicas como diastolicas, entre otras. | |
ES2963111T3 (es) | Derivados de 4-(1,3,4-oxadiazol-2-il)piridina-2(1H)-ona como inhibidores de la histona desacetilasa 6 (HDAC6) para el tratamiento de infecciones E.G | |
RU2007128080A (ru) | Производные пирролидиния в качестве мускариновых рецепторов мз | |
AR054102A1 (es) | Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas | |
AR050711A1 (es) | Derivados arilsulfonilestilbeno para el tratamiento y/o prevencion de afecciones del sistema nervioso central | |
ECSP088257A (es) | Derivados de amida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |